In This Section

Sharon J. Diskin, PhD
Sharon J. Diskin

Dr. Diskin's research is focused on translational genomics in childhood cancers. Her laboratory seeks to identify the genetic basis of childhood cancers by combining quantitative computational methods with rigorous "wet-lab" experimental approaches. In parallel, she has developed, and is applying, a proteogenomic approach to identify novel immunotherapeutic targets for high-risk and relapsed pediatric malignancies.



Subscribe to be notified of changes or updates to this page.

2 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.


Dr. Diskin is trained in genomics and computational biology and has a multi-disciplinary research program. Along with her colleagues, she couples integrative computational analyses of large-scale data such as next generation DNA/RNA sequencing, single nucleotide polymorphism (SNP) genotyping, epigenetic profiling, 3D chromatin looping, and mass spectrometry, with rigorous experimental validation. Her goal is to help improve outcomes for children diagnosed with high-risk childhood cancers.

She is currently working to identify genetic risk factors and their biological relevance in neuroblastoma, and her lab identified the first germline copy number variant (CNV) associated with neuroblastoma. Collaboratively, her team also established the genetic basis of sporadic neuroblastoma and demonstrated that genes targeted by neuroblastoma-associated germline variants not only influence tumor initiation by promoting malignant transformation, but are also required for maintenance of the malignant phenotype.

Other projects in Dr. Diskin's lab focus on defining the role of structural variation in neuroblastoma tumorigenesis, with her team identifying a rare ~550 kb germline deletion on chromosome 16 associated with neuroblastoma. In parallel, the lab found that somatic structural variant (SV) breakpoints are enriched in genes involved in neurodevelopment, and identified a novel tumor suppressor disrupted by SVs in neuroblastoma.

In addition, Dr. Diskin is investigating optimal immunotherapeutic drug targets for neuroblastoma, and has developed an integrative proteogenomic approach that combines cell surface mass spectrometry with RNA sequencing from neuroblastoma and a large set of normal pediatric and adult tissues. As a result, several proteins have been prioritized as candidate immunotherapeutic targets and are undergoing additional validation and functional studies.

Finally, Dr. Diskin often collaborates to develop new computational methods for cancer genomics and proteomics, with recent examples include CODEX, a method to improve normalization and DNA copy number detection from exome sequencing data, and GiaPronto, a web-based analytical tool for mass spectrometry data used worldwide.



Education and Training

BS, Villanova University (Computer Science), 1992

MS, University of Pennsylvania (Computer Science), 2002

PhD, University of Pennsylvania (Genomics and Computational Biology), 2008

Titles and Academic Titles


Associate Professor of Pediatrics

Professional Memberships

American Association of Cancer Research, 2005-

American Society of Human Genetics, 2009-

Professional Awards

American Association of Cancer Research Scholar in Training Award, 2005, 2008, 2009

American Society of Human Genetics Trainee Award, 2009

Distinguished Research Trainee Award, Children's Hospital of Philadelphia, 2010

American Association of Cancer Research Scholar in Training Award, 2010

William Guy Forbeck Research Foundation Scholar, 2010-2014

Publication Highlights

Links of Interest